The synthetic tripeptide arsenical 4-( N -( S -glutathionylacetyl)amino) phenylarsenoxide (GSAO) is an angiogenesis inhibitor that targets the mitochondria of actively dividing but not quiescent endothelial cells, arresting their proliferation and causing apoptosis. Normal endothelial cells are much more sensitive to GSAO than tumor cells. To elucidate the mechanism of tumor cell resistance, we identifi ed yeast genes that are necessary for resistance to GSAO. Methods: We screened a genome-wide set of 4546 Saccharomyces cerevisiae deletion strains to identify GSAO-sensitive strains. We then examined GSAO accumulation in and proliferation activity of endothelial cells ( 
Tumor expansion and metastasis depend on tumor blood vessel formation, or angiogenesis. We recently described a synthetic tripeptide trivalent arsenical (GSAO; (4-( N -( S -glutathionylacetyl)amino) phenylarsenoxide)) that causes increases in superoxide levels, proliferation arrest, mitochondrial depolarization, and apoptosis of proliferating, but not quiescent, endothelial cells in vitro and that inhibits angiogenesis in vivo ( 1 ) . GSAO inactivates the mitochondrial adenine nucleotide translocase (ANT) by cross-linking the matrix-facing thiols of Cys-160 and Cys-257 ( 1 , 2 ) . ANT exchanges matrix ATP for cytosolic ADP across the inner mitochondrial membrane and is the key component of the mitochondrial permeability transition pore ( 3 , 4 ) .
The strong selectivity of GSAO for proliferating relative to nonproliferating endothelial cells is a consequence of the higher mitochondrial calcium ion levels in proliferating cells. ANT is a calcium receptor whose conformation and activity changes on binding of calcium ions; calcium-bound ANT has a much stronger affi nity for GSAO than the calcium-free form. This mechanism is supported by the crystal structure of the calcium-free form of bovine ANT ( 5 ) . The cysteine pair (Cys-160 and Cys-257) that GSAO cross-links in the calcium-replete form are 18.2 Å apart in the calcium-free structure, which is at least twice the distance required for them to interact with trivalent arsenicals.
GSAO is also a selective inhibitor of proliferating endothelial cells compared with tumor cells ( 1 ) : The IC 50 (i.e., concentration required for 50% inhibition) for proliferation arrest of bovine or human primary endothelial cells was 10 -15 μ M in a 3-day proliferation assay, whereas 3-to more than 32-fold higher concentrations of GSAO were necessary to induce proliferation arrest in all tumor cell lines tested. These cell culture observations were borne out in vivo ( 1 ) ; we found that systemic administration of GSAO to immunodefi cient mice bearing human pancreatic BxPC-3 carcinoma tumors reduced tumor vascularity but had no effect on the proliferative index of the tumor cells.
To elucidate the mechanism of the selectivity of GSAO for endothelial versus tumor cells, we screened a genome-wide set of Saccharomyces cerevisiae deletion strains to identify yeast genes that are necessary for resistance to GSAO. We used a bank of yeast homozygous diploid deletions for all nonessential genes from the Saccharomyces Gene Deletion Project ( 6 ) . The availability of the deletion strains has enabled the identifi cation of mechanisms by which yeast can protect themselves against oxidants such as inorganic hydroperoxide (H 2 O 2 ), organic peroxide (cumene hydroperoxide), lipid linoleic-13-hydroperoxide, and a superoxide generating agent (menadione) ( 7 , 8 ) , and it seemed likely that this approach would identify yeast genes necessary for GSAO resistance as well. The sheer number of deletion strains in the bank that we used (n = 4546) makes it likely that functions or pathways that confer resistance to GSAO will be identifi ed. After we identifi ed the yeast genes that were most important for GSAO resistance, we probed the function of corresponding genes and pathways in mammalian cells with pharmacologic interventions and transfected cells. We also used inhibitor studies to investigate the basis of the differential sensitivity of endothelial and tumor cells.
M ATERIALS AND M ETHODS

Chemicals
GSAO ( M r = 548) was produced as described previously ( 1 , 9 ) to a purity greater than 94% (as determined by high-performance liquid chromatography). The solid was dissolved in phosphatebuffered saline (PBS; 8.1 m M Na 2 HPO 4 , 1.5 m M KH 2 PO 4 , 138 m M Na Cl, 2.7 m M KCl, pH 7.0), and the concentration of active trivalent arsenical was measured by titrating with dimercaptopropanol and calculating the remaining free thiols with 5,5 ′ -dithiobis(2-nitrobenzoic acid) ( 1 ) . The titrated GSAO was sterile-fi ltered and stored at 4 °C in the dark until use. Stock solutions of GSAO were stable for at least 1 month and were diluted in sterile PBS just before use. Stock solutions of GSAO, buthionine sulfoximine (BSO; Sigma-Aldrich, St. Louis, MO), reduced glutathione (Sigma-Aldrich), reduced glutathione ethyl ester (Sigma-Aldrich), and sodium orthovanadate (Sigma-Aldrich) were made in PBS. The pump inhibitors MK-571 (Cayman Chemical, Ann Arbor, MI) and pGp-4008 (Sigma-Aldrich) were dissolved in dimethyl sulfoxide.
Yeast Strains and Growth Conditions
BY4743 yeast with homozygous diploid deletions for all nonessential genes from the Saccharomyces Gene Deletion Project were obtained from EUROSCARF (Frankfurt, Germany) ( 6 ) . Cells were grown in liquid YEPD (2% wt/vol glucose, 2% wt/vol bacteriological peptone, and 1% yeast extract). Plates (96 well) containing 0.5 and 2 m M GSAO were prepared and stored overnight at 4 °C. Cells were seeded in the plates using a 96-pin replicator and incubated at 30 °C for 24 hours. Growth was measured by light scattering at 600 nm using a microplate reader (Thermomax Plus; Molecular Devices, Palo Alto, CA). Deletion strains that showed no or impaired growth relative to wild type at either concentration were scored as sensitive. GSAO at 2 m M had no effect on growth of wild-type yeast. These strains were then tested on plates containing a range of GSAO concentrations (0.001 -1 m M ).
Cell and Culture Conditions
Bovine aortic endothelial cells (BAECs) were from Cell Applications (San Diego, CA). HT1080 fi brosarcoma cells, Panc-1 and BxPC-3 pancreatic cancer cells, and Caco-2 cells were from the American Type Culture Collection (Manassas, VA). BAEC, HT1080, Panc-1, and Caco-2 cells were cultured in Dulbecco's modifi ed Eagle medium, and BxPC-3 cells were cultured in RPMI 1640 medium. All cells were supplemented with 10% fetal calf serum, 2 m M L -glutamine, and 5 U/mL penicillin -streptomycin (Gibco, Gaithersburg, MD). Trypsin -EDTA solution, which was used to detach cells from culture plates, was also from Gibco.
Madin-Darby canine kidney II (MDCKII) polarized epithelial cell lines and transfectants that overexpress multidrug resistance -associated proteins (MRPs) 1, 2, or 3 ( 10 , 11 ) were obtained from P. Borst, The Netherlands Cancer Institute, Amsterdam, as were human embryo kidney (HEK293) cells and transfectants overexpressing MRP4 ( 12 ) or MRP5 ( 13 ) . The mouse embryo fi broblast line MEF3.8, which lacks functional P-glycoprotein (P-gp) and Mrp1 and expresses very low levels of the breast cancer resistance protein Bcrp1 ( 14 ) , and the MEF/ Bcrp1 clone BA2 ( 15 ) , which overexpresses mouse Bcrp1, were kindly supplied by A. Schinkel, The Netherlands Cancer Institute, Amsterdam. The MEF/MDR1 clone H4, which overexpresses human P-gp, was produced in a manner directly analogous to the MEF/Bcrp1 clone ( 15 ) -i.e., by transducing MEF3.8 cells with the retroviral construct LZRS-MDR1-IRES-GFP vector and selecting clones by fl ow cytometry for GFP expression and fl uorescent substrate (rhodamine 123). Cells were grown and maintained as adherent monolayers in Dulbecco's modifi ed Eagle medium containing 10% supplemented calf serum (Cosmic; Hyclone, Tauranga, New Zealand), 100 μ g/mL penicillin, and 60 μ g/mL streptomycin.
GSAO Flux in BAECs Treated With Drug Transport Inhibitors and Glutathione Modulators
BAECs were seeded at a density of 7 × 10 4 cells per well in 12-well plates and allowed to adhere overnight. Cells were then treated with buthionine sulfoximine (BSO) (200 μ M ) or reduced glutathione (2 m M ) for 24 hours at 37 °C or with MK-571 (25 μ M ), pGp-4008 (5 μ M ) or sodium o -vanadate (500 μ M ) for 10 min at 37 °C. GSAO was then added to a fi nal concentration of 100 μ M , and the cells were incubated for 4 hours at 37 °C. The cells were then washed three times with ice-cold PBS, lysed in 0.3 mL of 70% nitric acid and 0.7 mL of PBS, and kept at 4 °C until analysis. Lysates were diluted 10-fold in PBS and analyzed for arsenic atoms (which are released from GSAO in the presence of 70% nitric acid) using an Elan 6100 inductively coupled plasma spectrometer (Perkin Elmer Sciex Instruments, Shelton, CT). Results are from triplicate determinations from two or three separate experiments (see fi gure legends for details).
Cell Proliferation Assays
BAEC, BxPC-3, HT1080, and Panc-1 cells were seeded at densities of 1.5 × 10 3 , 1 × 10 4 , 3 × 10 3 , and 6 × 10 3 cells per well, respectively, in 96-well plates and allowed to adhere overnight. The medium was then changed, and the cells were cultured for an additional 72 hours. Viable attached cells were determined by incubating cells with the tetrazolium salt MTT (Sigma, St. Louis, MO), which is metabolized by viable cells to form insoluble purple formazan crystals. Dimethyl sulfoxide was added to lyse the cells, the contents of the wells were homogenized by shaking, and the absorbance at 550 nm was measured. Cell growth in the untreated control sample was normalized as 100%, and growth for all treatments was expressed as percentage of control. IC 50 values (i.e., the drug concentration that inhibits cell proliferation by 50%) for GSAO were determined from these plots. Results are from duplicate determinations from four to seven separate experiments (see fi gure legends for details).
Cytotoxicity Assays
Log phase cells were seeded in 96-well pates at a density of 500 cells per well in 100 μ L of medium and allowed to attach for 4 -16 hours. Increasing drug concentrations (i.e., a doubling at each step) were applied along the long plate axes, in an additional 100 μ L of medium per well, with quadruplicate repeats for each concentration. After 4 days, while cells in untreated control wells were still subconfl uent, cells were stained with 200 μ L per well of Sybr I Green (Molecular Probes, Eugene, OR) that had been diluted 1 : 4000 in hypotonic lysis buffer (10 m M Tris pH 8.0, 2.5 mm EDTA, 0.1% Triton X-100). Following equilibration of the stain with lysed cells for at least 2 days at 4 °C in the dark, relative cell numbers were determined by measuring fl uorescence on a Wallac Victor 1420 multilabel counter (Perkin Elmer, Shelton, CT) with 485 nm excitation and 530 nm emission fi lters. The IC 50 values were determined from the mean of at least three independent assays.
Immunoblot Analysis of MRP1 and MRP2
Cell lysates were prepared by resuspending cells at 4 × 10 7 cells/mL in lysis buffer (10 m M Tris pH 8, 0.1% Triton X-100, 10 m M MgCl 2 , 2 m M CaCl 2 , and proteinase inhibitor cocktail (Sigma-Aldrich), freeze -thawed on dry ice three times, and centrifuged at 20 000 g for 5 min at 4 °C to pellet nuclei and debris. Soluble protein content was determined by the Bradford assay (Bio-Rad, Hercules, CA). Samples were then mixed with Laemmli buffer and heated at 65 °C for 5 minutes because boiling has been shown to cause aggregation of transporter proteins. Samples were analyzed by sodium dodecyl sulfate -polyacrylamide gel electrophoresis on 3% -8% gradient gels (NuPAGE; Invitrogen, Carlsbad, CA) with 20 μ g of protein per lane. Separated proteins were electro blotted to polyvinylidene difl uoride membranes (Millipore, Bedford, MA). Membranes were blocked overnight at 4 °C in 5% nonfat milk powder in PBS with 0.1% Tween 20. Identical blots were probed with rat monoclonal antibody to human MRP1, MRPr1 ( 18 ) , diluted 1 : 5000 (Alexis Biochemicals, San Diego, CA) or mouse monoclonal antibody to MRP2, M2III-6 ( 18 ) diluted 1 : 1000 (Alexis Biochemicals). The lower half of one blot was probed with a monoclonal antibody to α -tubulin, YL1/2 ( 19 ) (Abcam, Cambridge, UK), as a loading control. Bound anti bodies were detected with horseradish peroxidase -conjugated goat anti -rat or goat anti -mouse polyclonal secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) and visualized by enhanced chemoluminescence (SuperSignal West Pico, PerBio, Rockford, IL).
Measurement of Cellular Glutathione
BAEC, HT1080, Panc-1, and BxPC-3 cells were seeded in 75-cm 2 fl asks and allowed to adhere overnight. The medium was replaced with fresh medium containing 10% fetal calf serum, and the cells were cultured for 72 hours. Cells were detached, counted, and centrifuged at 3000 g for 5 min at 4 °C. Dried pellets of 2 × 10 6 cells were kept at − 80 °C until use. Reduced glutathione concentration was measured using a Bioxytech GSH-400 Assay Kit (Oxis Health Products, Portland, OR) according to the manufacturer's instructions.
Statistical Analyses
Data are presented as means with 95% confi dence intervals (CIs). All variables were examined for normality and homogeneity of variance. Normality of the distributions was assessed using the Shapiro-Wilk test. One-way analysis of variance and posthoc tests, which were parametric or nonparametric as appropriate, were used to compare mean values. All analyses were performed using the statistical package SPSS version 13 (SPSS, Chicago, IL). All tests of statistical signifi cance were two-sided, and P values < .05 were considered statistically signifi cant.
R ESULTS
Identifi cation of Sensitive Yeast Strains
The growth of the S. cerevisiae deletion strains was compared in the absence and presence (of 0.5 or 2 m M ) GSAO for 24 hours at 30 °C. Of the 4546 deletion strains, 88 (1.9%) were found to be sensitive to GSAO (Supplementary fi gure avail able at http://jncicancerspectrum.oxfordjournals.org/jnci/ content/ vol97/ issue20 ). The IC 50 for GSAO was determined for each of the 88 strains using a range of GSAO concentrations from 0.001 to 1 m M . For reference, the IC 50 for GSAO ranged from greater than 4 m M (wild type, BY4743) to 0.027 m M (ycf1 deletion strain). The 27 most sensitive strains, in order of sensitivity, are shown in Fig. 1 . For clarity of presentation, the different categories of yeast gene(s) and the corresponding mammalian homo logue(s) necessary for resistance to GSAO have been discussed together.
Drug Transporters
The yeast strain lacking YCF1 was the most sensitive to GSAO, with an IC 50 of 0.027 m M ( Fig. 1 ) . Given that GSAO resembles a glutathione S -conjugate of phenylarsenoxide and that Ycf1 mediates transport of glutathione S -conjugates into the yeast vacuole, it is possible that Ycf1 recognizes GSAO as a detoxifi ed phenylarsenoxide. Other highly sensitive deletion strains include those lacking several other genes implicated in vacuole biogenesis (especially PEP3, but also KCS1 and VID28; Fig. 1 ), underscoring the crucial role of the vacuole for resistance to GSAO. The strain lacking YAP1, a transcriptional activator of YCF1 ( 20 , 21 ) , was also sensitive to GSAO (supplementary fi gure).
YCF1 encodes an ATP-binding cassette (ABC) protein ( 22 ) . Mammalian ABC proteins include P-glycoprotein, P-gp (ABCB1), the breast cancer resistance protein BCRP (ABCG2), and the multidrug resistance -associated proteins (MRP) 1 to MRP7. In mammalian cells, MRP1 has been characterized as a transporter of multivalent organic anions, preferentially glutathione S -conjugates ( 21 , 23 ) but also sulfate conjugates, glucuronides, oxidized glutathione, and complexes of reduced glutathione with As(III) ( 24 , 25 ) . Ycf1, therefore, is considered the structural and functional homologue of human MRP1 ( 26 ) . P-gp, the product of the MDR1 gene ( 27 , 28 ) , and BCRP transport amphiphilic compounds with apparently no other defi ning features ( 29 ) , whereas the MRP class members are predominantly transporters of organic amines ( 37 ) .
To determine if GSAO is transported from mammalian cells by an MRP class transporter, BAECs were treated with GSAO for 4 hours in the presence or absence of the MRP inhibitor 
MK-571 ( 23 )
. Treatment with MK-571 resulted in 2.2-fold increase in accumulation of arsenic in BAECs ( Fig. 2, B ) . MRP activity requires energy in the form of ATP, and a similar increase in arsenic accumulation was observed in cells treated with sodium o -vanadate, an ATPase type P inhibitor ( Fig. 2, B ) . By contrast, treatment with pGp-4008, a specifi c inhibitor of P-gp ( 30 ) , did not result in arsenic accumulation. These results are consistent with the idea that GSAO is a substrate for MRP in BAECs.
The observation that inhibition of MRP activity resulted in accumulation of GSAO (as measured by an increase in arsenic) in BAECs implies that blocking MRP activity should also decrease the IC 50 of GSAO for inhibition of BAEC proliferation. Indeed, treatment of BAECs with MK-571 caused a dosedependent decrease in the GSAO IC 50 ( Fig. 2, C ) . The IC 50 decreased by 10-fold, from 10.2 μ M in the absence of MK-571 to 1.1 μ M at the highest concentration of MK-571 (mean difference = 9.2 μ M ; 95% CI on the difference = 7.8 to 10.6 μ M ). Treatment with the P-gp inhibitor pGp-4008 did not change the GSAO IC 50 ( Fig. 2, D ) . In the absence of GSAO, neither MK-571 nor pGp-4008 alone affected BAEC proliferation at the highest concentration used (data not shown). The results presented in Fig. 2 demonstrate that GSAO is pumped from endothelial cells by MRP.
To identify the MRP subclass proteins that are responsible for exporting GSAO from mammalian cells, we treated transfected cells that overexpress MRP1, MRP2, MRP3, MRP4, MRP5, P-gp, or BCRP with increasing concentrations of GSAO and compared their proliferation with that of GSAO-treated parental cells ( Figs. 3, A -C 
Glutathione Synthesis Pathway Components
When the 88 genes conferring resistance to GSAO were grouped into functional categories, the most striking feature was the abundance of genes involved in sulfur metabolism and sulfate assimilation. Moreover, of the 13 S. cerevisiae strains with the highest sensitivity to GSAO, eight lacked genes whose products are involved in sulfate assimilation or in sulfur amino acid and glutathione synthesis ( Figs. 1 and 4 ) . The most sensitive deletion strains in this group (cys3, cys4 , and gsh1) are all defective in the central pathway of cysteine and glutathione synthesis. No alternative pathway for de novo cysteine production is available to S. cerevisiae in the absence of these genes. All of the genes encoding enzymes involved in sulfate assimilation (from 
SO 4
2 -to γ -glutamylcysteine) are included in the 27 most sensitive deletion strains (met14, met16, ecm17, met10, and met17 ) . The MET8 gene product controls the expression of both PAPS reductase (encoded by MET16) and sulfi te reductase (encoded by ECM17), and the met8 deletion strain was among the most sensitive to GSAO. The carbon backbone of homocysteine derives from L -aspartate ( Fig. 4 ) . Most of the enzymes of the homocysteine biosynthetic pathway (Hom3, Hom2, and Hom6) were required for full GSAO resistance. Met28, Cbf1, and Yap1 are transcription factors that participate in the control of sulfur metabolism by regulating the expression of γ -glutamylcysteine synthase (GSH1), which encodes the rate-limiting enzyme in glutathione synthesis ( 33 ) .
The fi nding that so many genes involved in sulfur metabolism and sulfate assimilation are necessary for GSAO resistance indicates that integrity of the cysteine and glutathione synthesis pathways (up to γ -glutamylcysteine; Fig. 4 ) is essential for the yeast to protect itself against this compound. It is of interest that GSH2, which encodes glutathione synthase (the enzyme that converts γ -glutamylcysteine to glutathione), does not appear to be essential for GSAO resistance. This fi nding is in accordance with the fi nding that the gsh2 deletion strain copes well with oxidative stress induced by hydrogen peroxide and superoxide anions ( 34 ) ; thus, it would also be expected to be tolerant of the oxidative stress induced by GSAO. Furthermore, γ -glutamylcysteine has been shown to be at least as good as glutathione in protecting yeast against an oxidant challenge ( 35 ) . These fi ndings suggest that γ -glutamylcysteine can substitute for the antioxidant pro perties of glutathione in eukaryotic cells. By contrast with the involvement of MET genes that are required for glutathione synthesis, the genes that are specifi c to the synthesis of methionine were not implicated in the resistance against GSAO.
To probe the dependence on glutathione level of the sensitivity of mammalian cells to GSAO, we treated the BAECs with exogenous glutathione (to increase glutathione levels) or with inhibitors of glutathione production (to decrease levels) before treating the cells with GSAO. Treatment with glutathione or with glutathione ethyl ester, a membrane-permeable derivative of glutathione, substantially blunted GSAO inhibition of BAEC proliferation ( Fig. 5, A ) . Conversely, blocking de novo synthesis of glutathione with BSO, an inhibitor of γ -glutamylcysteine synthase, enhanced the sensitivity of BAECs to GSAO by almost 100-fold ( Fig. 5, B ) . The glutathione content of BAECs following BSO treatment was 15% that of untreated cells.
These results raised the possibility that the selectivity of GSAO for endothelial versus tumor cells refl ects differences in glutathione levels. Indeed, we found a striking association between the GSAO IC 50 for inhibition of proliferation and the cellular glutathione level of the different cells ( Fig. 5, C ) .
Linkage Between MRP1 Activity and Cellular Glutathione in Resistance to GSAO
Our fi ndings that the activity of MRP1 and MRP2 and the glutathione synthesis machinery contribute to differences in the sensitivity of different mammalian cells to GSAO refl ects the fact that these processes are not independent. For example, the yeast YAP1 gene encodes a transcription factor that controls the expression of both YCF1 and GSH1 [ γ -glutamylcysteine synthase ( 20 , 36 ) ]. In addition, effl ux of drugs from mammalian cells via MRP1 involves cellular glutathione, although the precise mechanism by which glutathione participates in MRP1 function differs from drug to drug. The effl ux of glutathione conjugates and of glucuronate conjugates by MRP1 is independent of cellular glutathione content ( 21 ) , whereas vincristine and anthracyclines are cotransported with glutathione ( 37 ) . On the other hand, effl ux of glucuronide conjugates by MRP is enhanced by glutathione, although it is not cotransported ( 25 ) .
We therefore investigated whether cellular glutathione levels moderate MRP-mediated effl ux of GSAO in endothelial cells. Cotreatment of BAECs with high concentrations of both BSO and MK-571 did not increase arsenic accumulation to a greater extent than treatment with either inhibitor alone ( Fig. 5, D ) and had no additional effect on the IC 50 for GSAO inhibition of proliferation beyond that of treatment with either inhibitor alone (data not shown). Presumably, MRP1 was not functional in cells treated with very high BSO concentrations (i.e., 200 μ M ) because cellular glutathione levels were insuffi cient for transport activity; therefore, MK-571 had no additional effect in such cells. In BAECs treated with lower concentrations of BSO, the remaining MRP1 activity was inhibited by MK-571, as measured by further decreases in the IC 50 for GSAO (data not shown). 
Relationship of MRP1 and MRP2 and Glutathione Synthesis Activity to the Selectivity of GSAO for Endothelial Versus Tumor Cells
To investigate the relative contributions of MRP1 and MRP2 activity and cellular glutathione levels to the selectivity of GSAO for endothelial versus tumor cells, we examined the effects of MK-571 and BSO on the IC 50 of GSAO for inhibiting proliferation of endothelial and tumor cells. Treatment with MK-571 or BSO reduced the GSAO IC 50 in both endothelial and tumor cells ( Fig. 6 ). In addition, the IC 50 s for GSAO inhibition of BAECs (IC 50 = 1.06 μ M ; 95% CI = 0.71 to 1.42 μ M ) and HT1080 cells (IC 50 = 1.22 μ M ; 95% CI = 0.58 to 2.17 μ M ) were the same when MRP activity was blocked ( Fig. 6 ). This result suggested that the difference in the sensitivity of BAEC and HT1080 cells for GSAO (IC 50 , these IC 50 s were still higher than in BAECs and HT1080 cells. Thus, it appeared that some mechanism(s) other than MRP1 and MRP2 activity in these cell lines were contributing to their resistance to GSAO.
One likely mechanism was increased glutathione levels. When cells were treated with the highest concentration of BSO used 4 . Diagram of the cysteine and glutathione synthesis pathway and genes necessary for GSAO resistance. Open boxes denote gene products that were found to be important for resistance of Saccharomyces cerevisiae to GSAO. Shaded boxes denote gene products that, when deleted, confer the highest sensitivity to GSAO. Ovals denote regulatory gene products that are involved in the resistance to GSAO. Deletion strains for met3 and met2 were not available for testing. 
D ISCUSSION
Until recently, our understanding of the mechanism of drug action in mammalian cells has been limited to probing specifi c proteins or pathways. Gene array technology has enabled a global appreciation of the response of cells or tissues to a drug, but it does not report on how cells or tissues manage a drug prior to gene expression. The recent availability of a genomewide set of S. cerevisiae deletion strains has afforded a very precise way to identify which gene products mediate or blunt the effects of a drug. In this study, we elucidated the mechanism of selectivity of an angiogenesis inhibitor for endothelial versus tumor cells by screening a set of 4546 deletion strains. Importantly, we showed that mammalian proteins that were closely related to the gene products identifi ed as mediating resistance in yeast were of functional importance to resistance in mammalian cells.
Our results indicate that the activity of the drug transporters MRP1 and/or MRP2 and of cellular glutathione levels are largely responsible for the selectivity of GSAO for endothelial cells as compared with fi brosarcoma and pancreatic carcinoma cell lines. Multidrug transporter proteins of the ABC superfamily, which include not only MRP1 through MRP7 but also P-gp and BCRP, are believed to contribute to drug resistance and chemotherapy failure by active effl ux of cytotoxic agents from cancer cells ( 37 ) . MRP1, MRP2, MRP3, P-gp, and BCRP have all been shown to confer resistance to a variety of natural products and anticancer drugs, collectively including the taxanes, Vinca alkaloids, anthracyclines, epipodophyllotoxins, and camptothecin-class topoisomerase I inhibitors, whereas MRP4 and -5 confer resistance to nucleoside analogs ( 29 ) . In addition to a role in drug resistance, multidrug transporters infl uence the uptake, elimination, and disposition of substrate drugs by virtue of their polarized expression on epithelial and endothelial cell membranes in the intestine, The data points and error bars are the means with upper 95% confi dence intervals (CIs) and are representative of two experiments, each performed in quadruplicate. ***, P <.001 compared with control; *, P = .02 compared with control; #, P <.001 compared with GSAO-treated cells. B ) BAECs were treated with increasing concentrations of GSAO and buthionine sulfoximine (BSO) to deplete cellular glutathione. The 50% inhibitory concentration (IC 50 ) for GSAO inhibition of BAEC proliferation was determined in a 72-hour proliferation assay. The data points and error bars are the means with upper 95% CIs from three to four determinations, each performed in duplicate.
C ) Association of cellular glutathione content with the selectivity of GSAO for inhibition of endothelial versus tumor cell proliferation. The IC 50 for GSAO was determined from a 72-hour proliferation assay. GSAO IC 50 values are means with 95% CIs from six independent determinations. Glutathione content is the mean with 95% CIs of two determinations, each performed in duplicate. The IC 50 and glutathione content values for each cell type are statistically signifi cantly different from each other ( P <.01 to P <.001). D ) To determine whether MRP and glutathione act independently to protect cells from GSAO, BAECs were incubated without a modulator (Nil), with 25 μ M MK-571 for 10 min, with 200 μ M BSO for 24 hours, with BSO followed by MK-571, or with 2 m M GSH for 24 h and then with 100 μ M GSAO for 4 hours. GSAO accumulation was determined by measuring GSAO arsenic atoms using inductively coupled plasma spectrometry. Results are means with upper 95% CIs of two experiments performed in triplicate. ***, P <.001 compared with control; *, P = .014 compared with control.
by guest on May 1, 2016 http://jnci.oxfordjournals.org/ Downloaded from liver, kidney, blood -brain barrier, and placenta, where they mediate directional transport of diverse endogenous compounds, metabolites, drugs, and xenobiotics ( 37 ) . We also found that enzymes involved in glutathione biosynthesis are important to GSAO resistance, most likely because of the involvement of glutathione in the process by which GSAO is transported out of the cell. Yeast Ycf1 ( 38 , 39 ) and human MRP1 ( 40 ) appear to transport As(III) as a complex with three molecules of glutathione. It is likely that the arsenical moiety of GSAO reacts similarly with one or two molecules of glutathione before it is removed by Ycf1 or by MRP1 or MRP2, hence the absolute reliance on glutathione for its elimination. The fi nding that the deletion strains missing Arr3 and its transcription activator Arr1 were not sensitive to GSAO exposure implies that the arsenical moiety is not cleaved from the phenyl ring of GSAO by S. cerevisiae to any substantial extent. S. cerevisiae exports unconjugated As(III) into the medium via Arr3 (also called Acr3), a carrier protein that is located in the plasma membrane ( 41 ) . The lack of evidence for GSAO-induced cytoskeleton or DNA damage also supports this notion, because As 2 O 3 , sodium arsenite (NaAsO 2 ), and dimethylarsinic acid (C 2 H 7 AsO 2 ) disrupt microtubule function, weaken the mitotic spindle, and arrest the cell cycle at mitosis in human and hamster cell lines ( 42 -44 ) . Diverse DNA repair systems are also impaired by sublethal doses of arsenicals. As(III) inhibits the two major pathways eliminating DNA base damage and helix distortions, base excision repair ( 45 ) and nucleotide excision repair ( 46 ) , whereas NaAsO 2 causes DNA strand breaks, oxidative DNA adducts, and DNA -protein cross-links ( 47 -49 ) .
We conclude that the peptide arsenical GSAO is a selective angiogenesis inhibitor because endothelial cells are less effi cient than tumor cells at exporting GSAO from the cell. Tumor cells, by contrast, are more resistant to GSAO because they have higher MRP1 and/or MRP2 activity and higher cellular glutathione levels, which combine to enhance export of GSAO. These fi ndings raise the possibility that GSAO could be converted from an antiendothelial to an anti -tumor cell compound by blocking MRP1 activity or glutathione synthesis in tumor cells. Alternatively, GSAO's antiangiogenic activity could be enhanced by targeting these processes in proliferating endothelial cells. For instance, GSAO could be combined with the glutathione synthesis inhibitor BSO that has been shown to decrease glutathione levels in human tumors in a phase I clinical trial ( 50 ) . The S. cerevisiae screen we have employed should have more general use in defi ning the mechanism of action of other human therapeutics. Such knowledge will better defi ne a drug's strengths and weaknesses, which will help with the optimization of its use and rational design of analogues. 
